Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757146 | 0.93 | BRAF (0.55) | BRAFGSK3A | |
| SCHEMBL5780116 | 0.90 | BRAF (0.48) | BRAFGSK3A | |
| SCHEMBL13757162 | 0.89 | BRAF (0.49) | BRAF | |
| SCHEMBL6807093 | 0.88 | BRAF (0.49) | BRAF | |
| SCHEMBL13757143 | 0.88 | BRAF (0.49) | BRAF | |
| SCHEMBL4506618 | 0.88 | BRAF (0.47) | BRAF | |
| SCHEMBL5635761 | 0.87 | BRAF (0.51) | BRAF | |
| SCHEMBL4494468 | 0.87 | BRAF (0.48) | BRAF | |
| SCHEMBL4489645 | 0.87 | BRAF (0.49) | BRAF | |
| SCHEMBL14602785 | 0.86 | BRAF (0.55) | BRAFGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569568-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569568-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070032492-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032492-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-7166628-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166628-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032492-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1RN | BRAF 3631/4885GSK3A 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.